X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 19.3 35.0 55.0% View Chart
P/BV x 18.5 3.3 555.0% View Chart
Dividend Yield % 0.6 0.2 401.2%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
IPCA LABS
Mar-17
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs877643 136.4%   
Low Rs424503 84.2%   
Sales per share (Unadj.) Rs223.4254.4 87.8%  
Earnings per share (Unadj.) Rs31.116.1 193.3%  
Cash flow per share (Unadj.) Rs40.329.8 135.3%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.2 440.5%  
Book value per share (Unadj.) Rs219.5194.6 112.8%  
Shares outstanding (eoy) m33.07126.20 26.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.3 129.2%   
Avg P/E ratio x20.935.7 58.7%  
P/CF ratio (eoy) x16.119.2 83.9%  
Price / Book Value ratio x3.02.9 100.6%  
Dividend payout %16.16.2 258.6%   
Avg Mkt Cap Rs m21,50472,300 29.7%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,1286,960 16.2%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m7,38932,106 23.0%  
Other income Rs m167226 74.0%   
Total revenues Rs m7,55632,332 23.4%   
Gross profit Rs m1,7934,448 40.3%  
Depreciation Rs m3041,730 17.6%   
Interest Rs m366241 152.1%   
Profit before tax Rs m1,2902,703 47.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309675 45.7%   
Profit after tax Rs m1,0272,028 50.7%  
Gross profit margin %24.313.9 175.2%  
Effective tax rate %23.925.0 95.8%   
Net profit margin %13.96.3 220.1%  
BALANCE SHEET DATA
Current assets Rs m3,68117,340 21.2%   
Current liabilities Rs m3,1239,559 32.7%   
Net working cap to sales %7.624.2 31.2%  
Current ratio x1.21.8 65.0%  
Inventory Days Days89100 89.2%  
Debtors Days Days5957 103.2%  
Net fixed assets Rs m7,68520,779 37.0%   
Share capital Rs m331252 131.0%   
"Free" reserves Rs m6,67024,499 27.2%   
Net worth Rs m7,25924,553 29.6%   
Long term debt Rs m9553,517 27.1%   
Total assets Rs m11,95739,595 30.2%  
Interest coverage x4.512.2 37.0%   
Debt to equity ratio x0.10.1 91.8%  
Sales to assets ratio x0.60.8 76.2%   
Return on assets %11.75.7 203.4%  
Return on equity %14.28.3 171.4%  
Return on capital %20.710.5 197.6%  
Exports to sales %39.448.6 80.9%   
Imports to sales %5.714.2 40.0%   
Exports (fob) Rs m2,90815,617 18.6%   
Imports (cif) Rs m4214,571 9.2%   
Fx inflow Rs m3,44515,617 22.1%   
Fx outflow Rs m7035,828 12.1%   
Net fx Rs m2,7439,790 28.0%   
CASH FLOW
From Operations Rs m1,4402,764 52.1%  
From Investments Rs m-1,089-1,432 76.1%  
From Financial Activity Rs m-353-1,591 22.2%  
Net Cashflow Rs m-1-259 0.6%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NATCO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 25, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS